Molecularly, RMS can be divided into fusion-positive and fusion-negative tumours (in reference of chromosomal translocations affecting mainly FOXO1 and PAX3 or PAX7 genes), a stratification criterion that has been recently demonstrated to be a powerful predictor of prognosis [1,2], since both subtypes differ considerably in their clinical behaviour. Here, PAX3 is linked to neoplasm.